5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
1 citations
,
December 2005 in “The Journal of Urology” Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.
1707 citations
,
December 2003 in “The New England Journal of Medicine” Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
January 2023 in “DIGITAL HEALTH” Most men using teledermatology for hair loss treatment saw improved hair and self-esteem, with some experiencing side effects.
November 2018 in “Studies in Medical Sciences” 15 citations
,
December 2006 in “Clinical interventions in aging” 5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.
October 2024 in “Actas Dermo-Sifiliográficas” Finasteride and dutasteride can increase beard thickness in men.
1 citations
,
January 1997 in “ACP journal club”
1 citations
,
July 2017 in “The Journal of Urology” Low-dose finasteride and dutasteride reduce PSA levels by 27.8% in men with male androgenetic alopecia.
98 citations
,
January 2013 in “Journal of The American Academy of Dermatology” Dutasteride may help stabilize Frontal Fibrosing Alopecia, but more research is needed.
7 citations
,
December 2019 in “Pharmaceutics” Taking Dutasteride with Ketoconazole can increase Dutasteride's effects and side effects.
16 citations
,
October 2017 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Dutasteride may protect the brain in early Parkinson's disease.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
50 citations
,
March 2017 in “PeerJ” Using finasteride or dutasteride may cause long-lasting erectile dysfunction.
70 citations
,
November 2013 in “The BMJ” Tamsulosin for enlarged prostate may increase the risk of severe low blood pressure, especially when starting or restarting the medication.
July 2024 in “Actas Dermo-Sifiliográficas” Finasteride and dutasteride do not significantly change beard thickness in men.
May 2023 in “Elsevier eBooks” Minoxidil, finasteride, and dutasteride are treatments for hair loss.
January 2006 in “Revista Argentina de Urología” Finasteride lowers prostate cancer risk but may increase high-grade tumors and sexual side effects.
10 citations
,
May 2010 in “Analytica Chimica Acta” New tests detect finasteride and dutasteride in urine quickly and easily.
July 2025 in “Reactions Weekly” 62 citations
,
January 2004 in “PubMed” 5alpha-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT, offering symptom relief and potential future uses.
40 citations
,
April 1999 in “Drugs” Finasteride treats enlarged prostate, improves urinary flow, but may cause sexual side effects.
October 2023 in “The Journal of urology/The journal of urology” Higher testosterone and DHT levels are not linked to urinary symptoms in men.
December 2025 in “The AAPS Journal” Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.
September 2010 in “Zhonghua miniao waike zazhi” Tamsulosin hydrochloride is safe and effective for long-term treatment of urinary symptoms in BPH patients.
1 citations
,
January 2009 in “CRC Press eBooks” Finasteride increases hair count and improves hair growth with low risk of side effects.
2 citations
,
March 2018 in “Current Opinion in Urology” 5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
13 citations
,
August 2013 in “Journal of pharmaceutical sciences” Researchers created a skin patch that delivers two drugs for treating enlarged prostate, which may improve patient use and dosage control.
2 citations
,
August 2016 in “British Journal of Clinical Pharmacology” The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.
July 2025 in “International Journal of Dermatology” Topical finasteride may be safer than oral finasteride, but more research is needed.